Nektar Therapeutics(NKTR)
SAN FRANCISCO, CABiotechnology
Focus: Nektar Therapeutics is a San Francisco-based biotech company developing small molecules and biologics across oncology, infectious diseases, immunology, dermatology, and metabolic diseases. The company is publicly traded (NKTR) with a highly R&D-focused portfolio in early-to-mid stage development.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
10
Should You Work at Nektar Therapeutics?
AI assessmentNektar is a high-risk, high-science biotech suitable for researchers and clinical development professionals willing to bet on pipeline catalysts, but cash runway and lack of marketed products present material employment stability risk.
Why Work Here
- Portfolio spans five therapeutic areas with 30 active programs, providing broad exposure to oncology (dominant), immunology, and metabolic disease development
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$98M
Pipeline & Clinical Trials
Placebo
PsoriasisClinical Trials (2)
NCT07711418A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Phase 3Help build intelligence for Nektar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.